CNR1 and neurodegenerative disease: MAGL inhibition prolongs 2-AG action in the brain through CB1 and CB2 receptors and reduces de biosynthesis of arachidonic acid, the precursor of proinflammatory prostanoids, for these reasons it has emerged as an interesting target for the treatment of neurodegenerative diseases [53].